In mice, use of CD28 superagonist has been shown to increase the % of Treg cells, and protect from Rheumatoid Arthritis mediated bone destruction.
Marlo M Zaiss, Jean-Pierre David, et al. (2010) J Immunol 184: 7238-7246.
Ancell anti-CD28 antibody clone ANC28.1/5D10 has been characterized as a superagonist.
This mAb has been found to be capable of stimulating IL-2 production from Jurkat cells without T Cell Receptor engagement.
Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses
Kevin M. Dennehy, Thomas Hünig, et al. The Journal of Immunology, 2006, 176: 5725-5729.